Skip to Content

Soliris, this biopharma company’s lucrative drug for rare blood disorders, helped infuse 24% sales growth in the second quarter of 2015.

Company Information

Location
Cheshire, CT
Industry
Pharmaceuticals
Sector
Health Care
Fortune 500 Rank941
Fortune 500 Profilehttp://fortune.com/fortune500/alexion-pharmaceuticals-941/
Current Streak2
Years on List4
CEO
David L. Hallal
Websitehttp://www.alxn.com

Revenue, Net Income

Revenue Past Four Quarters2,267
Net Income Past Four Quarters589

Growth Rates

EPS 3 yr Annual Growth Rate43%
Rev 3 yr Annual Growth Rate40%
Total Return 3 yr Annual Rate22%
Beat S&P 3 yr Total Return?
yes

Rank

EPS Growth Rank53
Revenue Growth Rank25
Total Return Rank
86